HBC RECEIVES APPROVAL FROM HEALTH CANADA FOR QUALIFIED HEALTH CLAIMS FOCUSED ON MAINTAINING HEALTHY LEVELS OF FERRITIN AND HEMOGLOBIN AND THE BLOOD COMPONENTS REQUIRED FOR OXYGEN TRANSPORT

Disclosure of large shareholding

KEY INFORMATION RELATING TO THE SUBSEQUENT OFFERING

PRIVATE PLACEMENT SUCCESSFULLY PLACED

CONTEMPLATED PRIVATE PLACEMENT – INTENDED TRANSFER OF LISTING TO OSLO BØRS

PROGO’s BIOACTIVE PEPTIDES TO SUPPORT HEALTHY IRON LEVELS TO BE LAUNCHED IN THE U.S.

HBC’S APPLICATION TO HEALTH CANADA FOR UNIQUE QUALIFIED HEALTH CLAIMS IS PROGRESSING VERY WELL AND A POSITIVE CONCLUSION IS EXPECTED DURING OCTOBER 2020

ANNOUNCES THE USE OF A VIRTUAL PLATFORM TO RECRUIT COVID-19 PATIENTS IN CANADA TO THE PHASE 2 TRIAL. WILL ALSO ASSESS THE IMPACT OF OMEGO ON HOSPITALISED PATIENTS WITH SEVERE FORMS OF COVID-19 IN MEXICO AND BRAZIL

SHARE CAPITAL INCREASE REGISTERED

New study highlights the potential of OmeGo® as a prophylactic therapy for Asthma and COPD